CLDX Earnings Date: Nov 9, 2026 (Estimated) — Celldex Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CLDX's next earnings date?
Celldex Therapeutics, Inc. (CLDX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.02 on revenue of $722,636.
How did CLDX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Celldex Therapeutics, Inc. posted EPS of -$0.94 versus the -$1.06 estimate, a beat of 11.3%. Revenue was $22,000 against a $734,917 estimate. The stock's 1-day post-earnings move was +0.4%.
How much does CLDX stock move after earnings?
CLDX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.06 | -0.94 | +11.32% | $22,000 | ✅ Beat | +0.36% | +2.53% | -4.52% |
| 2026-05-19 | Q1 2026 | -1.13 | -1.18 | -4.42% | $15,000 | ❌ Miss | +2.49% | +4.98% | +7.56% |
| 2026-02-25 | Q4 2025 | -1.00 | -1.22 | -22.00% | $100,000 | ❌ Miss | -0.58% | -4.15% | +3.02% |
| 2025-11-10 | Q3 2025 | -0.89 | -1.01 | -13.48% | $0 | ❌ Miss | +7.50% | +14.69% | +24.35% |
| 2025-02-27 | Q4 2024 | -0.73 | -0.71 | +2.74% | $1.2M | ✅ Beat | +1.28% | +5.02% | -1.87% |
| 2024-11-06 | Q3 2024 | -0.68 | -0.64 | +5.88% | $3.2M | ✅ Beat | -4.20% | -2.86% | -3.11% |
| 2024-02-26 | Q4 2023 | -0.74 | -0.83 | -12.16% | $4.1M | ❌ Miss | +27.76% | +37.43% | +9.77% |
| 2023-11-02 | Q3 2023 | -0.68 | -0.81 | -19.12% | $1.5M | ❌ Miss | +8.20% | +7.37% | +33.07% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $22K total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Grant | 68.2% | $15K | -97.9% | $3.2M | $3.7M | $645K | $723K |
| Service | 31.8% | $7K | 0.0% | $3K | $8K | $50K | $7K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.